2-(2,5-二甲基苯氧基)丙酸 | 18996-04-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-(2,5-二甲基苯氧基)丙酸
• 英文名称: racem. 2.5-Dimethylphenoxy-propionsaeure
• 英文别名: 2-(2,5-dimethyl-phenoxy)-propionic acid；α-(2.5-Dimethyl-phenoxy)-propionsaeure；2-(2,5-Dimethyl-phenoxy)-propionsaeure；2-(2,5-dimethylphenoxy)propanoic acid
• CAS: 18996-04-8
• 化学式: C₁₁H₁₄O₃
• mdl: MFCD03419316
• 分子量: 194.23
• InChiKey: MJJBTCMCULRVQR-UHFFFAOYSA-N

物化性质

• 熔点：
  102-103 °C
• 沸点：
  315.4±27.0 °C(Predicted)
• 密度：
  1.116±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2918990090

反应信息

• 作为反应物：
  描述：

  2-(2,5-二甲基苯氧基)丙酸 在 sodium hydroxide 作用下， 以 四氢呋喃 、 水 为溶剂， 生成 2-(2,5-dimethylphenoxy)-1-propanol
  参考文献：
  名称：

  Intermediates for the synthesis of benzoxazol- and benzothiazolamine

  摘要：

  苯并噁唑胺和苯并噻唑胺衍生物具有抗缺氧特性，这些化合物在缺氧治疗中很有用。这些化合物是从特定的苯并噁唑和苯并噻唑胺中间体中产生的。

  公开号：

  US05010198A1
• 作为产物：
  描述：

  2,5-dimethyl-phenol; potassium-compound 在 alkali 作用下， 生成 2-(2,5-二甲基苯氧基)丙酸
  参考文献：
  名称：

  Azzolina; Collina; Ghislandi, Il Farmaco, 1993, vol. 48, # 10, p. 1401 - 1416

  摘要：

  DOI：

文献信息

• Benzoxazol-and benzothiazolamine derivatives, useful as anti-anoxic
  申请人：Janssen Pharmaceutica N.V.

  公开号：US04861785A1

  公开（公告）日：1989-08-29

  Benzoxazol-and benzothiazolamine derivatives having anti-anoxic properties which compounds are useful in the treatment of anoxia.

  苯并噁唑胺和苯并噻唑胺衍生物具有抗缺氧特性，这些化合物在缺氧治疗中很有用。
• GHRH analogs
  申请人：The Administrators of The Tulane Educational Fund

  公开号：EP0413839A1

  公开（公告）日：1991-02-27

  There is provided a novel series of synthetic GHRH analog peptides which are extremely potent in stimulating the release of pituitary GH in animals, including humans, which are resistant to enzymatic degradation in the body in view of the provision of the omega-guanidino lower alkyl group at the terminal 28-position of the peptide.

  提供了一系列新型合成GHRH类似肽，这些肽在动物体内，包括人体内，极具激发垂体生长激素释放的强效能力，这是因为在肽的末端28位置提供了omega-胍基较低烷基基团，使其具有抗酶降解的特性。
• Synthetic GHRH analogs
  申请人：The Administrators of The Tulane Educational Fund

  公开号：EP0277626A2

  公开（公告）日：1988-08-10

  Human pancreatic GRF (hpGRF), rat hypothalamic GRF (rGRF) and porcine hypothalamic GRF (pGRF) have been earlier characterized and synthesized. The invention provides synthetic peptides which are extremely potent in stimulating the release of pituitary GH in animals, including humans, which have resistance to enzymatic degradation in the body, and which have the sequence: Q¹-CO-R₂-R₃-Ala₄-Ile₅-Phe₆-Thr₇-R₈-Ser₉-R₁₀-Arg₁₁-R₁₂-R₁₃-­R₁₄-R₁₅-Gln₁₆-R₁₇-R₁₈-Ala₁₉-Arg₂₀-Lys₂₁-Leu₂₂-R₂₃-R₂₄-R₂₅­-Ile₂₆-R₂₇- R₂₈-NH-Q² wherein Q¹ is an omega or alpha-omega substituted alkyl, Q² is a lower omega-guanidino-alkyl group. R₂ is Ala,D-Ala,or D-N-Methyl-Ala R₃ is Asp,D-Asp,Glu,or D-Glu R₈ is Asn,D-Asn,Ser, or D-Ser R₁₀ is Tyr or D-Tyr R₁₂ is Lys, D-Lys Arg or Orn R₁₃ is Val or Ile R₁₄ is Leu or D-Leu R₁₅ is Gly,N-Methyl-Gly, or D-Ala R₁₇ is Leu or D-Leu R₁₈ is Tyr or Ser R₂₃ is Leu or D-Leu R₂₄ is Gln or His R₂₅ is Asp,D-Asp,Glu, or D-Glu R₂₇ is Met,D-Met,Ala,Nle,Ile,Val,Nva,Leu R₂₈ is Asn or Ser The peptides as well as nontoxic salts thereof may be administered to animals, including humans and cold-­blooded animals, to stimulate the release of GH and may be used diagnostically.

  人胰腺促肾上腺皮质激素（hpGRF）、大鼠下丘脑促肾上腺皮质激素（rGRF）和猪下丘脑促肾上腺皮质激素（pGRF）早先已被表征和合成。本发明提供的合成肽在刺激包括人在内的动物释放垂体促肾上腺皮质激素方面具有极强的效力，在体内具有抗酶降解的能力，其序列如下： Q¹-CO-R₂-R₃-Ala₄-Ile₅-Phe₆-Thr₇-R₈-Ser₉-R₁₀-Arg₁₁-R₁₂-R₁₃-R₁₄-R₁₅-Gln₁₆-R₁₇-R₁₈-Ala₁₉-Arg₂₀-Leu₂₁-Leu₂₂-R₂₃-R₂₄-R₂₅-Ile₂₆-R₂₇- R₂₈-NH-Q² 其中 Q¹ 是欧米茄或α-欧米茄取代烷基、 Q² 是低级欧米伽胍基烷基。 R₂ 是 Ala、D-Ala 或 D-N-Methyl-Ala R₃ 是 Asp、D-Asp、Glu 或 D-Glu R₈ 是 Asn、D-Asn、Ser 或 D-Ser R₁₀ 是 Tyr 或 D-Tyr R₁₂ 是 Lys、D-Lys Arg 或 Orn R₁₃ 是 Val 或 Ile R₁₄ 是 Leu 或 D-Leu R₁₅ 是 Gly、N-甲基-Gly 或 D-Ala R₁₇ 是亮氨或 D-亮氨 R₁₈ 是 Tyr 或 Ser R₂₃ 是 Leu 或 D-Leu R₂₄ 是 Gln 或 His R₂₅ 是 Asp、D-Asp、Glu 或 D-Glu R₂₇ 是 Met、D-Met、Ala、Nle、Ile、Val、Nva、Leu R₂₈ 是 Asn 或 Ser 这些肽及其无毒盐可用于动物，包括人类和冷血动物，以刺激 GH 的释放，也可用于诊断。
• CCL5 inhibitors
  申请人：LAPKO INC.

  公开号：US11318111B2

  公开（公告）日：2022-05-03

  Compounds, pharmaceutically acceptable salts, esters, prodrugs, and pharmaceutical compositions thereof are disclosed that are useful for inhibition of the biological activity of CCL5 on mammalian cells, as well as methods of treatment for diseases involving the increased biological activity of CCL5.

  所公开的化合物、药学上可接受的盐、酯、原药及其药物组合物有助于抑制 CCL5 在哺乳动物细胞上的生物活性，以及治疗涉及 CCL5 生物活性增加的疾病的方法。
• Design, synthesis and structure–activity relationship studies of novel phenoxyacetamide-based free fatty acid receptor 1 agonists for the treatment of type 2 diabetes
  作者：Zheng Li、Xuekun Wang、Xue Xu、Jianyong Yang、Qianqian Qiu、Hao Qiang、Wenlong Huang、Hai Qian

  DOI：10.1016/j.bmc.2015.09.010

  日期：2015.10

  The free fatty acid receptor 1 (FFA1) has attracted extensive attention as a novel antidiabetic target in the last decade. Several FFA1 agonists reported in the literature have been suffered from relatively high molecular weight and lipophilicity. We have previously reported the FFA1 agonist 1. Based on the common amide structural characteristic of SAR1 and NIH screened compound, we here describe the continued structure-activity exploration to decrease the molecular weight and lipophilicity of the compound 1 series by converting various amide linkers. All of these efforts lead to the discovery of the preferable lead compound 18, a compound with considerable agonistic activity, high LE and LLE values, lower lipophilicity than previously reported agonists, and appreciable efficacy on glucose tolerance in both normal and type 2 diabetic mice. (c) 2015 Published by Elsevier Ltd.